"Raltegravir" and "Zidovudine"

Phase 1Small molecule

"Raltegravir" and "Zidovudine" is one of 11 small molecule programs targeting Tropical Spastic Paraparesis. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Tropical Spastic ParaparesisActive, not recruiting

Tropical Spastic ParaparesisPhase 1

Active, not recruiting

Competition

Competitive Landscape

12 competitors in Tropical Spastic Paraparesis

#DrugCompanyPhaseTrials

Neoral

Novartis

Approved

—2

Epivir

GGlaxo Dba Glaxosmithkline

Retrovir

Depakote

1 5

Poteligeo

Ciclosporin

1 7

Tamibarotene

SSyros Pharmaceuticals

Phase 3

1 8

Remicade

Aubagio

Hu-Mik- Beta-1

NNational Cancer Institute (NCI)

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Tropical Spastic Paraparesis1 trial

Effect of Raltegravir in Patients With Acute Tropical Spastic Paraparesis - Human T-Lymphotropic Virus 1 Infection

Completed·UUniversidad Peruana Cayetano Heredia·Phase 1·NCT02655471·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for "Raltegravir" and "Zidovudine". U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — "Raltegravir" and "Zidovudine" compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for "Raltegravir" and "Zidovudine". EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Universidad Peruana Cayetano Heredia company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: UUniversidad Peruana Cayetano Heredia

"Raltegravir" and "Zidovudine"

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Tropical Spastic Paraparesis1 trial

References

Drug Info

Quick Facts

Related News